United Kingdom: MHRA Approval and NHS Access Rules
Post-Brexit, the UK's MHRA runs its own approval process separate from the EMA, and NHS access to GLP-1 drugs runs through NICE cost-effectiveness review.
By the GLP Semaglutide editorial team · Last updated June 2, 2026
Since Brexit, the UK's Medicines and Healthcare products Regulatory Agency (MHRA) runs an independent approval process, separate from the EU's EMA, though the two agencies' decisions on the same drug often (but not always) align in outcome and timing.
NHS access runs through NICE
Even after MHRA approval, NHS-funded access to a drug typically depends on a cost-effectiveness appraisal by the National Institute for Health and Care Excellence (NICE), which can recommend, restrict, or decline routine NHS funding based on its assessment.
Private prescriptions are a separate pathway
Where NHS funding is restricted, some patients access GLP-1 drugs through private prescription, generally at higher out-of-pocket cost. NICE guidance and NHS England's own published criteria are the authoritative sources for current NHS eligibility rules.
Primary sources